Lung Cancer Vaccine: Can Intismeran Extend Survival?

What is the personalized lung cancer vaccine trial testing?

Merck and Moderna's August announcement of positive phase 3 melanoma findings has sharpened interest in where personalized cancer vaccines could work next. A separate lung cancer study addresses a different treatment setting: disease that has already spread. Success after melanoma surgery provides a reason to investigate, but cannot establish effectiveness against metastatic lung cancer. The companies described their melanoma findings as initial results from an ongoing trial. [Merck and Moderna announcement](https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/)

The National Cancer Institute lists V940-013 as an active phase 2 study for metastatic squamous non-small cell lung cancer. Participants receive pembrolizumab and chemotherapy alongside either intismeran or placebo. Researchers will compare overall survival and the time before cancer grows or spreads. This design tests the vaccine's additional contribution while both groups receive anticancer treatment. [NCI trial description](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-08355)

How could intismeran work with existing lung cancer treatments?

Intismeran, also called V940 or mRNA-4157, is designed using mutations identified in an individual patient's tumor. Its messenger RNA carries instructions for up to 34 neoantigens: abnormal protein targets associated with that cancer. Presenting these targets to the immune system is intended to generate a focused T-cell response. The treatment is therefore tailored to an existing tumor; its design does not establish that it will successfully control that tumor. [Intismeran mechanism](https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/)

Pembrolizumab blocks PD-1, an immune checkpoint that can restrain T cells. Combining recognition of tumor targets with checkpoint blockade offers a biological rationale for the study. There is already randomized evidence supporting the underlying treatment combination: the KEYNOTE-407 trial, published in the New England Journal of Medicine in 2018, found that pembrolizumab plus chemotherapy improved overall and progression-free survival compared with chemotherapy alone in metastatic squamous lung cancer. Those findings establish a comparator for vaccine research, rather than evidence for intismeran itself. [NCI checkpoint explanation](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors), [KEYNOTE-407 publication](https://www.nejm.org/doi/full/10.1056/NEJMoa1810865)

What evidence would show that the vaccine is worth adding?

The trial's survival outcomes matter because a treatment can stimulate immunity without necessarily helping patients live longer. Delaying progression and extending life are also different achievements: improvement in one should not be presented as proof of the other. When results emerge, their interpretation should consider the size of any benefit, uncertainty around the estimates and duration of follow-up. These are the questions raised by the study design, not benefits already demonstrated by this lung cancer vaccine. [NCI trial objectives](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-08355)

Safety will also shape the clinical value of adding another therapy. Checkpoint inhibitors can cause fatigue, rash and diarrhea, and sometimes inflammation affecting the lungs, bowel, liver, endocrine glands or other organs. The vaccine combination requires its own assessment; an encouraging result in another cancer cannot settle its safety in this population. Patients considering research participation should discuss their existing illnesses, previous treatments and the study's monitoring requirements with the trial team. [NCI immunotherapy safety information](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors)